|
|
|
|
|
|
Sponsored by: |
Karolinska University Hospital |
Information provided by: | Karolinska University Hospital |
ClinicalTrials.gov Identifier: | NCT00211159 |
Memory loss and difficulties with thinking associated with Alzheimer's disease (AD) may be due to a deficiency in the brain of a fatty acid named DHA. The aim of this trial is to see if dietary supplementation with a preparation, rich in DHA, will halt cognitive impairment in AD patients
Condition | Intervention |
Alzheimer's Disease |
Drug: EPAX 1050TG |
Genetics Home Reference related topics: | Alzheimer disease |
MedlinePlus related topics: | Alzheimer's Disease |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Efficacy Study |
Official Title: | Omega-3 Fatty Acid Treatment of 174 Patients With Mild to Moderate Alzheimer's Disease (OmegAD): a Randomized Double-Blind Trial |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria: Alzheimer's disease with MMSE 15-30, living in own homes, treated with stable dose of acetylcholine esterase inhibitor for >3 months and remaining on that treatment for the study period
Exclusion Criteria: Already treated with omega-3 fatty acids, NSAIDs, warfarin, being an alcohol abuser, suffering from serious concomitant disease or not having a caregiver
Sweden | |||||
Karolinska University Hospital Huddinge | |||||
Stockholm, Sweden, S-141 86 |
Karolinska University Hospital |
Principal Investigator: | Tommy Cederholm, MD, PhD | Karolinska University Hospital |
Study ID Numbers: | OmegAD#1 |
First Received: | September 13, 2005 |
Last Updated: | February 7, 2007 |
ClinicalTrials.gov Identifier: | NCT00211159 |
Health Authority: | Sweden: Swedish National Council on Medical Ethics |
|
|
|
|